Radiolabeled Cyclic Arginine-Glycine-aspartic (Rgd)-Conjugated Iron Oxide Nanoparticles As Single-Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI) Dual-Modality Agents for Imaging of Breast Cancer

Shengming Deng,Wei Zhang,Bin Zhang,Ruoyu Hong,Qing Chen,Jiajia Dong,Yinyiin Chen,Zhiqiang Chen,Yiwei Wu
DOI: https://doi.org/10.1007/s11051-014-2845-9
IF: 2.533
2015-01-01
Journal of Nanoparticle Research
Abstract:Ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs) modified with a novel cyclic arginine-glycine-aspartate (RGD) peptide were made and radiolabeled as single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) dual-modality agents for imaging of breast cancer. The probe was tested both in vitro and in vivo to determine its receptor targeting efficacy and feasibility for SPECT and MRI. The radiochemical syntheses of 125I-cRGD-USPIO were accomplished with a radiochemical purity of 96.05 ± 0.33 %. High radiochemical stability was found in fresh human serum and in phosphate-buffered saline. The average hydrodynamic size of 125I-cRGD-USPIO determined by dynamic light scattering was 51.3 nm. Results of in vitro experiments verified the specificity of the radiolabeled nanoparticles to tumor cells. Preliminary biodistribution studies of 125I-radiolabeled cRGD-USPIO in Bcap37-bearing nude mice showed that it had long circulation half-life, high tumor uptake, and high initial blood retention with moderate liver uptake. In vivo tumor targeting and uptake of the radiolabeled nanoparticles in mice model were visualized by SPECT and MRI collected at different time points. Our results strongly indicated that the 125I-cRGD-USPIO could be used as a promising bifunctional radiotracer for early clinical tumor detection with high sensitivity and high spatial resolution by SPECT and MRI.
What problem does this paper attempt to address?